JAPMA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gupta, A. K.
Right arrow Articles by Malkin, K. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gupta, A. K.
Right arrow Articles by Malkin, K. F.

Journal of the American Podiatric Medical Association, Vol 90, Issue 10 502-507, Copyright © 2000 by American Podiatric Medical Association

JOURNAL ARTICLE

Ciclopirox nail lacquer and podiatric practice

AK Gupta and KF Malkin
Department of Medicine, Sunnybrook and Women's College Health Sciences Center (Sunnybrook Site), Toronto, Ontario, Canada. agupta@execulink.com

Ciclopirox 8% nail lacquer has recently been approved by the US Food and Drug Administration (FDA) for the management of mild-to-moderate dermatophytic onychomycosis not involving the lunula. Previously, the agents that were approved for the treatment of dermatophytic pedal onychomycosis--griseofulvin, itraconazole, and terbinafine--were administered orally. When ciclopirox nail lacquer is used, it is recommended that the infected nail undergo debridement by a health-care professional as frequently as monthly. It is important to be aware of the circumstances under which debridement of the mycotic nail may be considered medically necessary and therefore potentially eligible for reimbursement by third-party payers. For many nail presentations, nail debridement is an important component of a treatment protocol involving either the oral medications or the topical lacquer, as it serves to reduce the fungal load and ameliorate symptoms. With the availability of a new FDA-approved topical treatment alternative, it remains to be seen if podiatrists will embrace the definitive treatment of onychomycosis using the newer oral agents, the new nail lacquer, or both in combination with nail debridement to treat the disease.


This article has been cited by other articles:


Home page
 J. Am. Podiatr. Med. Assoc.Home page
M. A. Brenner, L. B. Harkless, R. W. Mendicino, and J. C. Page
Ciclopirox 8% Nail Lacquer Topical Solution for the Treatment of Onychomycosis in Patients with Diabetes: A Multicenter, Open-Label Study
J Am Podiatr Med Assoc, May 1, 2007; 97(3): 195 - 202.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Podiatr. Med. Assoc.Home page
M. B. Jennings, R. Pollak, L. B. Harkless, F. Kianifard, and A. Tavakkol
Treatment of Toenail Onychomycosis with Oral Terbinafine Plus Aggressive Debridement: IRON-CLAD, a Large, Randomized, Open-Label, Multicenter Trial.
J Am Podiatr Med Assoc, November 1, 2006; 96(6): 465 - 473.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Podiatric Medical Association.